AnaCardio receives patent grant in Europe for AC01

Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced that European patent EP4346820 has been issued by the European Patent Office (EPO), securing the use of AC01/HM01 as an inotropic agent. The patent is co-owned by AnaCardio AB and Helsinn Healthcare SA and provides protection in all major European markets. The expiry date of this patent is June 2, 2042.

Patrik Strömberg, AnaCardio CEO, commented: “We are pleased to have been granted an additional patent that protects our lead candidate AC01, and that will secure extended European market exclusivity into the 2040s” .

Melanie Rolli, Helsinn Group CEO, commented: “We are delighted with the issuance of this European patent, which secures the use of AC01/HM01 as an inotropic agent until 2042. This milestone highlights our commitment to innovative treatments for heart failure.”